Last reviewed · How we verify

Preventive treatment of episodic migraine in adults — Treatment Landscape & Competitive Intelligence

Preventive treatment of episodic migraine in adults (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Preventive treatment of episodic migraine in adults, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Qulipta ATOGEPANT AbbVie Calcitonin Gene-related Peptide Receptor Antagonist [EPC] Calcitonin gene-related peptide type 1 receptor 2021-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie · 1 drug in Preventive treatment of episodic migraine in adults

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Preventive treatment of episodic migraine in adults:

Cite this brief

Drug Landscape (2026). Preventive treatment of episodic migraine in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/preventive-treatment-of-episodic-migraine-in-adults. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing